PharmAla Files Patent for Novel MDXX Molecule PharmAla-1
Patent Filing Follows Year of Preclinical Research, Academic PublicationVANCOUVER, British Columbia, July 31, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings...
Clinical Trial
Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr
Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023 Spero to receive $30...
Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly
Webinar Being Held on August 8, 2023 at 12:00 p.m. Eastern TimeSAN DIEGO, July 31, 2023 (GLOBE NEWSWIRE) -- Crinetics...
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
WALTHAM, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology...
INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2023...
Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023
MINNEAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted...
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
Nes-Ziona, Israel, July 31, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
Recce Pharmaceuticals to Present at the 2023 Military Health System Research Symposium (MHSRS)
SYDNEY, Australia, July 31, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing...
Neurona Therapeutics Appoints James Stutz as Chief Financial Officer and Chief Business Officer
SAN FRANCISCO, July 31, 2023 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for...
Daré Bioscience Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth
Grant Funds Will Support Proof-of-Concept Target Validation Studies for Preclinical Development of a Potential New Approach for the Prevention and...
Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome
Independent Data Monitoring Committee recommended REVEAL Phase 1/2 trial continuation and proceeding with dosing of second patient based on encouraging...
Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Initial data expected in first half of 2024NOVATO, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)...
Immutep Quarterly Activities Report Q4 FY23
Media Release Late-stage & registrational trial progress: TACTI-004 Phase III - Positive feedback received from US FDA for planned registrational...
180 Life Sciences Corp. Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress Appetite
PALO ALTO, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180LS” or the “Company”), today...
60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects
Patent provides exclusive use of tafenoquine for prevention of malaria in malaria-naive individuals in Canada until late 2035.Tafenoquine is the...
Appendix 4C – Q4 FY23 Quarterly Cash Flow Report
Highlights: ATH434-201 Phase 2 study on track to complete enrollment in Q3 2023 with top-line data expected by the end...
Spago Nanomedical interim report January-June 2023
LUND, SE / ACCESSWIRE / July 31, 2023 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) Tumorad® into clinicJANUARY - JUNE IN BRIEFNet...
Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy
No indication that drug product or manufacturing issues contributed to rare events of retinal vasculitisConfirmed seven total events of non-occlusive/occlusive...
Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS
89% and 84% of patients were maintained on ≥12- and ≥16-week dosing intervals, respectively, throughout the two-year period, while sustaining their...
4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023
4D-150 clinical efficacy endpoints for evaluable patients in all three cohorts (n=14) at 36 weeks Table for 4D-150 clinical efficacy...